Meeting
2020 ASCO Virtual Scientific Program
Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.
Authors
Brian Andrew Jonas
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Brian Andrew Jonas , Courtney Denton Dinardo , Keith Pratz , Andrew Wei , Wan-Jen Hong , Brenda Chyla , Yinghui Duan , Jalaja Potluri , Michael Werner , Daniel Aaron Pollyea
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02203773 and NCT02287233
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7531)
DOI
10.1200/JCO.2020.38.15_suppl.7531
Abstract #
7531
Poster Bd #
304
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
First Author: Farhad Ravandi
Poster
2024 ASCO Annual Meeting
7+3 versus decitabine + venetoclax: A global, propensity-matched study comparing outcomes for both regimens in AML.
First Author: Varada Salimath
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey
Poster
2017 ASCO Annual Meeting
CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).
First Author: Eunice S. Wang